Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Thursday's Bonus Story Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably uneasy after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still living in one of the best periods in history to build wealth—especially if you think long-term and stick to time-tested principles. According to Green, this pullback isn't as severe as it feels. "Just last Wednesday, the Dow hit an all-time high," he noted, explaining that recent selling has more to do with valuation concerns and interest-rate uncertainty than any fundamental breakdown. Why the Market Pulled Back Why Wall Street is piling into the "Debasement Trade"
Wall Street has been making headlines lately for piling into a strange new money move. What they've dubbed the "Debasement Trade"... And it could affect you and your money in a MAJOR way. No one in the media does a better job of explaining all of this than Dr. David Eifrig. As a former Goldman Sachs Vice President, he has traded profitably through just about every stock market situation you can imagine, including Black Monday… That's why his latest warning deserves your attention. We've posted Dr. Eifrig's new work for free on our website right here. Green attributes the dip to two main concerns. First, investors are questioning elevated tech and AI valuations, particularly as earnings season brings those expectations into focus. Second, recent inflation data and slower hiring have tempered hopes that the Fed will cut rates in December. With the central bank emphasizing a "data-dependent" stance, markets are less confident that relief is coming this year. Why Selling Now Might Be the Wrong Move Rather than trying to predict next week's moves, Green encourages investors to zoom out. He calls himself "a long-term optimist" and points out that, historically, the market's trend has been upward. Traders may want to exercise short-term caution. But for long-term investors, dips often create opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable indicator in volatile markets is insider buying. Green says when officers and directors—people with access to non-public information—are buying shares of their own companies, it's worth noting. He recommends tracking insider trading activity to see which stocks executives are adding to, not just selling. Insiders aren't always right, but their actions can provide a useful signal when markets are shaky. A Biotech Breakout to Watch: GRAIL One sector Green is focused on is biotech, where artificial intelligence is accelerating drug development and lowering costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a simple blood draw. Green has used the test himself and says it's "a good feeling" to know you're clear of many deadly diseases—especially ones like pancreatic cancer that often aren't detected until late stages. With FDA fast-track status and potential insurance reimbursement on the horizon, Green views GRAIL's roughly $3 billion market cap as just a starting point. The Biotech Risk—and Big Pharma's Appetite Biotech comes with risk: most drug candidates don't make it through every clinical phase to approval. Still, large pharmaceutical companies such as Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) actively acquire promising small-cap assets to replace expiring patents. Green pointed to Johnson & Johnson (NYSE: JNJ) as an example: the company invested in a private prostate cancer drug before it received FDA approval—illustrating how aggressive Big Pharma can be when clinical data looks promising. He believes biotech is especially attractive now because healthcare is largely recession-resistant. People need treatment regardless of the economic cycle. For investors seeking steadier demand and lower volatility than high-flying AI names, sectors like healthcare, utilities, consumer staples, and food companies can be appealing. The American Dream Is Still Possible—But Mindset Matters Despite economic challenges, Green argues the American Dream remains attainable. He wrote The American Dream to counter the narrative that it's out of reach after seeing polls showing nearly 70% of Americans believe it's no longer achievable. His point: with low-cost investment tools, commission-free trading, and abundant information, building wealth has never been more accessible. The challenge is knowing what to do—and having the discipline to do it. He simplifies the math: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—so long as you save consistently and leave the money to compound. Creative Solutions for Today's Housing Market Housing may feel out of reach, but Green says there are alternatives. Mortgage rates have doubled and prices are up about 50% since the pandemic—but creative approaches can help. He shares his experience buying two houses with no money down by working directly with motivated sellers and assuming their mortgages through a contract-for-deed arrangement. It may not deliver the perfect home immediately, but it can help you start building equity sooner. Stay Focused on the Long Game Volatile markets come and go. What matters is how you respond. Whether it's tracking insider moves, exploring high-upside sectors like biotech, or simply committing to a disciplined savings plan, Green's message is clear: the American Dream is still within reach. Keep your eyes on the goal—and take the next right step.
| 
